ArticleInternational journal of women's health2026
Predictive Value of Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 Detection in Early Pregnancy for Gestational Diabetes Mellitus: A Case-Control Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) increases the risk of complications such as gestational hypertension, genital tract infections, preterm birth, and adverse perinatal outcomes including fetal distress and macrosomia. Identifying serum biomarkers in early pregnancy may aid in prevention and improve maternal and fetal outcomes. Aim: To evaluate the predictive value of placental growth factor (PIGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1) for GDM in early pregnancy. Methods: A retrospective case-control study was conducted including 140 pregnant women screened for GDM in early pregnancy. Seventy women diagnosed with GDM formed the observation group, and 70 women with normal glucose levels served as controls. Inclusion criteria were singleton pregnancies with complete laboratory data and delivery follow-up at the same hospital. Primary outcomes were serum PIGF and sFlt-1 levels, and their predictive value for GDM was assessed. Results: Pre-pregnancy BMI, fasting plasma glucose, HbA1c, HOMA-IR, and sFlt-1 levels were significantly higher in the observation group, while PIGF levels were lower. Pre-pregnancy BMI, PIGF, and sFlt-1 were independent predictors of GDM ( Conclusion: Lower PIGF and higher sFlt-1 levels in early pregnancy may be associated with GDM development and adverse outcomes. These biomarkers demonstrate potential predictive value, but large-scale prospective studies are required to confirm clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.